Cross-Disease Economic Context
ME/CFS economic burden is best understood not in isolation but in comparison with diseases whose severity, chronicity, and cost structures are comparable β and whose funding levels are not.
Table :
- Multiple sclerosis: Annual per-patient total cost USD 39,000β68,000 (U.S./Europe, varying by disability level); indirect costs 50β75% of total; NIH funding ~USD 115M/year; DMTs exist that modify disease course (Simoens 2022).
- Rheumatoid arthritis: Annual per-patient total cost USD 12,000β21,000 (biologic era, U.S./Europe); indirect costs ~40β60% of total; NIH funding ~USD 86M/year; multiple FDA-approved disease-modifying therapies (Hsieh et al. 2020).
- ME/CFS: Annual per-patient total cost USD 18,000β29,000 (U.S. IOM estimate); indirect costs ~66β73% of total; NIH funding ~USD 15M/year; zero disease-modifying therapies.
The cross-disease comparison reveals a pattern that cannot be explained by disease severity, prevalence, or economic burden β because ME/CFS is comparable to MS and RA on all three dimensions and receives 7β13% of their research funding per DALY. The three-order-of-magnitude burden:funding ratio gap is larger than can be explained by any single factor (diagnostic ambiguity, patient advocacy strength, PI pipeline, historical stigma). It likely reflects the interaction of all these factors β a structural neglect that is self-reinforcing: low funding then few researchers then slow progress then perceived as intractable then continued low funding. Breaking this cycle would require a funding intervention at the scale of the NIHβs response to HIV/AIDS in the 1980s or to Long COVID in 2020 β a recognition that the funding deficit is not marginal but structural. (Certainty: 0.35 β speculative interpretation of cross-sectional funding data; the self-reinforcing model is plausible but untested; alternative explanations include differences in advocacy infrastructure, disease recognition, and biomarker availability. Origin: synthesis from Phase 2 evidence landscape.)
Consequence: If the structural-neglect hypothesis is correct, the policy implication is that incremental funding increases will not close the gap β the neglect is self-stabilizing and requires a step-change intervention to disrupt. If the hypothesis is wrong and the gap reflects legitimate scientific difficulty, then incremental funding increases should produce proportional returns and the hypothesis is falsified by showing that additional ME/CFS funding generates discovery at a rate comparable to MS/RA funding. This is testable with a dedicated ME/CFS research program that includes an explicit evaluation component. Severity applicability: the structural-neglect hypothesis applies to the research enterprise as a whole; its downstream effects are felt most acutely by severe and very severe patients, who have the greatest need for treatment advances.